Boris Umylny

Biography

  Dr. Umylny has an undergraduate degree in Computer Science from Columbia University, and a PhD in Cell and Molecular Biology from the University of Hawaii. Professionally, Dr. Umylny has more than twenty years of hands-on expertise developing, selling, integrating, using, and maintaining complex enterprise software – initially for financial firms, and more recently (with Lumenogix) – for genomic and related science research. In 1992 Dr. Umylny co-founded Fusion Systems Japan, a Tokyo-based consulting and software development company specializing in financial systems development and integration for which he served as Vice President until selling the firm via an M&A transaction in 1999. In this capacity, Dr. Umylny was responsible for all development and deployment of electronic trading and order execution platforms where he also oversaw and managed integrations for most of the major brokerage firms operating in Asia, including Jardine Fleming, Deutsche Bank, Morgan Stanley, Paribas, First Boston, Credit Suisse, UBS, and Hitachi among many others. In 2001 Dr. Umylny enrolled in a PhD program at the University of Hawaii and later received his degree in December of 2006. He founded Japan Bioinformatics KK in December 2007 to develop Simbiot to provide an enterprise grade SaaS platform capable of serving the worldwide academic and commercial genomic research markets for storing and analyzing genomic (specifically NGS) data. From June 2011 to July 2012, concurrent with running Japan Bioinformatics, Dr. Umylny also served as CIO of GENEWIZ (which services approximately half of the US market for Sanger sequencing) where he was responsible for all aspects of development and integration of their enterprise wide IT platform. In June, 2013 Dr. Umylny co-founded Lumenogix, which acquired the assets of Japan Bioinformatics, and which took over and assumed all operations of the predecessor company.

Research Interest

 Cell and Molecular Biology